Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Synapsin-2 is a neuron-specific phosphoprotein that associates with the cytoplasmic surface of synaptic vesicles and binds to the cytoskeleton in presynaptic nerve terminals[1][2][6]. It is crucial for the regulation of neurotransmitter release and synaptic vesicle trafficking. Through alternative splicing, the SYN2 gene encodes the isoforms synapsin IIa and synapsin IIb, both of which play roles in maintaining synaptic vesicle pools and synaptic plasticity[1]. Synapsin-2 is implicated in normal synaptogenesis and neurotransmission, and its dysfunction is associated with several neuropsychiatric and neurodevelopmental disorders, including schizophrenia, autism, epilepsy, and bipolar disorder[2][3]. There are currently no widely recognized small molecule drugs or direct inhibitors/activators for Synapsin-2, but it is considered a protein of high therapeutic interest, particularly for neurological and psychiatric indications[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Synapsin-2 (SYN2).